Results of the phase 3 MOMENTUM study showed that the JAK1/JAK2 inhibitor momelotinib can provide treatment for the patient’s disease and also their anemia.
Aaron T. Gerds, MD, MS, assistant professor in medicine (Hematology and Medical Oncology) at the Cleveland Clinic, discusses how the results of the phase 3 MOMENTUM trial (NCT04173494) have shifted thinking toward the use of momelotinib for patients with myelofibrosis.
The JAK1/JAK2 inhibitor was compared with danazol in patients who had received prior JAK inhibitor therapy and were anemic. The results showed that patients with myelofibrosis given momelotinib had better control of their anemia, but also demonstrated spleen shrinkage and relief of some symptoms. According to Gerds, this shows that momelotinib can tackle 2 issues at once with patients by treating patients’ disease and also treating their anemia. Importantly, the drug has also proven its safety in comparison to danazol and also showed a durable response.
Transcription:
0:08 | Well, there's so much to unpack from the MOMENTUM study, a prospective randomized trial in patients with myelofibrosis pitting momelotinib vs danazol. Danazol was picked because it is an active drug that improves anemia in patients with myelofibrosis. So, clearly the first thing you go to is [compare] the anemia responses and clearly momelotinib can improve anemia in patients with myelofibrosis. But the other points are it can shrink spleens and it can improve symptoms, so if you think about it, from a certain perspective, it's like one-stop shopping. You get your JAK inhibitor plus your anemia drug all in one pill. To me, that is the major take home point of the MOMENTUM studies, that momelotinib can prove to be a very helpful therapy in the treatment of [patients with] myelofibrosis.
0:51 | Of course, as a clinical researcher, I had my eye on momelotinib as being the new backbone for a lot of our trials going forward in combination therapy, because it doesn't have the myelosuppressive effects of ruxolitinib [Jakafi] and still can treat the spleen and symptoms associated with myelofibrosis. There are some subtle things within the study I think are incredibly important. The one thing I like to point out is the fact that the rates of neuropathy were not high. That was an early concern during the development of momelotinib, that it might lead to neuropathies. But there were no differences between momelotinib and danazol on the MOMENTUM study in terms of the rates of neuropathy. So, I think that's really a key point is not only the efficacy, but really the safety of momelotinib.
Retrospective Data Highlight Impact of Dose Escalation of Regorafenib in mCRC
May 9th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
NGS and ctDNA Considered in Advanced Breast Cancer After Progression
May 3rd 2024During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Read More